Despite all the attention on this tragic problem and the emergence of proven protocols to prevent it, wrong-site surgeries persist. It's time to make them stop.
The European Medicines Agency (EMA) revises its guideline on minimizing risk in first-in-human trials to reflect changing practice and in light of a recent tragic incident.
